Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/40770
Title: Validation of G6PD point-of-care tests among healthy volunteers in Yangon, Myanmar
Authors: Nwe Nwe Oo
Germana Bancone
Lwin Zar Maw
Nongnud Chowwiwat
Pooja Bansil
Gonzalo J. Domingo
Moh Moh Htun
Kyaw Zin Thant
Ye Htut
Francois Nosten
Department of Medical Research (Lower Myanmar)
Mahidol University
PATH Seattle
Nuffield Department of Clinical Medicine
Keywords: Agricultural and Biological Sciences;Biochemistry, Genetics and Molecular Biology
Issue Date: 1-Apr-2016
Citation: PLoS ONE. Vol.11, No.4 (2016)
Abstract: © 2016 Oo et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. Primaquine and other 8-amnoquinoline based anti-malarials can cause haemolysis in subjects with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Correct diagnosis of G6PD status in patients is crucial for safe treatment of both relapsing stages of Plasmodium vivax and transmitting forms of Plasmodium falciparum. Lack of suitable point-of-care tests has hampered a much needed wide use of primaquine for malaria elimination. In this study we have assessed the performances of two qualitative tests, the fluorescent spot test (FST) and the G6PD CareStart test (CST), against the gold standard quantitative spectrophotometric assay in a population of 1000 random adult healthy volunteers living in Yangon, Myanmar. The prevalence of G6PD deficiency in the Bamar, Karen and in the whole sample set was 6.6% (10.1% in males), 9.2% (21.0% in males) and 6.8% (11.1% in males) respectively. The FST and CST showed comparable performances with sensitivity over 95% and specificity over 90%, however for cases with severe G6PD activity the FTS had improved performance. If used with a conservative interpretation of the signal, the CareStart test has the potential to be used in the field and, by allowing a wider use of primaquine, to help malaria elimination. Copyright:
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84962781978&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/40770
ISSN: 19326203
Appears in Collections:Scopus 2016-2017

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.